Pulmonary aspergillosis is not a single illness but a broad group of conditions caused by fungi in the genus Aspergillus. These molds release microscopic spores that are common in soil, dust and decaying vegetation. Most people inhale Aspergillus spores without becoming ill, because the immune system and the airways generally remove them efficiently. In vulnerable patients, however, the fungus can colonize damaged lung tissue, trigger intense allergic inflammation or invade blood vessels and surrounding organs. The invasive form is particularly dangerous: fungal hyphae can penetrate tissue and blood vessels, causing bleeding, tissue death and rapid deterioration. Chronic forms may develop more gradually in people with structural lung disease, while allergic disease can produce severe airway inflammation without fungal invasion.

The investigators retrospectively examined medical records from a single tertiary hospital, comparing patients treated before the COVID-19 period with those treated during the pandemic era. They evaluated temporal trends, patient characteristics, microbiological results, diagnostic markers, the interval between symptom onset and antifungal treatment, and short-term outcomes. This design allowed the researchers to observe how the population reaching the hospital changed over time, but it cannot by itself distinguish the effects of SARS-CoV-2 infection from other pandemic-related factors. Changes in referral patterns, diagnostic awareness, intensive-care capacity, use of immunosuppressive drugs and the availability of fungal testing could all have influenced the observed pattern.

The increase in case numbers was striking. Before the COVID-19 era, the annual number of pulmonary aspergillosis cases rose by an average of 1.49 cases per year. During the COVID-19 era, the average annual increase accelerated to 35.2 cases. That difference represents more than a simple fluctuation in hospital admissions and points to a major expansion in the number of patients being recognized or treated for the disease. The researchers caution that their results come from one hospital, so they cannot be assumed to represent all of China or other countries. Nevertheless, the scale of the change makes the finding important, particularly because pulmonary aspergillosis can be missed when its symptoms—fever, cough, shortness of breath, chest pain and fatigue—overlap with bacterial pneumonia, viral pneumonia and complications of critical illness.

The dominant identified species was Aspergillus fumigatus, which accounted for 54.87 percent of isolates. This species is the most frequently reported cause of human aspergillosis and is especially well adapted to growth at human body temperature. Its spores are small enough to reach the lower respiratory tract, where they can germinate when local defenses are impaired. Diagnosis is technically challenging because Aspergillus may be present in the environment or airway without causing invasive disease. Clinicians may combine chest computed tomography, respiratory cultures, microscopy, antigen tests and blood biomarkers to estimate whether the fungus is actively invading lung tissue. A positive culture alone does not always prove invasive infection, while a negative culture does not reliably exclude it.

One diagnostic signal was higher among patients treated during the COVID-19 era. The median serum concentration of (1,3)-β-D-glucan was 37.50 picograms per milliliter, compared with 28.60 picograms per milliliter in patients from the pre-COVID period. β-D-glucan is a component of the cell walls of many fungi, including Aspergillus, and can enter the bloodstream during fungal growth or tissue invasion. It is therefore used as an indirect marker of invasive fungal infection. However, the test is not specific to Aspergillus and can be affected by other infections, medical products and procedures. Another important test examined in the study was the galactomannan, or GM, index. Galactomannan is a polysaccharide released during Aspergillus growth, and a GM index above 0.5 was associated with poor outcome in the researchers’ initial statistical analysis.

Patients diagnosed during the COVID-19 era were also older. Their median age was 62 years, compared with 54 years among patients treated before the pandemic. At the same time, the interval from symptom onset to antifungal therapy became shorter: the median fell to 12 days from 19 days. Earlier treatment may reflect greater clinical suspicion, improved access to fungal diagnostics or more rapid recognition of high-risk patients. It could also indicate that patients were reaching hospital care in a more advanced or clinically obvious state. Antifungal drugs such as voriconazole, isavuconazole or liposomal amphotericin B are used according to the clinical form of disease, the patient’s condition and local patterns of drug resistance, but treatment decisions are complicated by toxicity, drug interactions and uncertainty in diagnosis. The study did not show that earlier therapy alone improved survival, but the shift is clinically meaningful because delays can allow invasive fungal disease to spread.

The analysis identified the patients most likely to experience a poor short-term outcome. In univariate analyses, influenza-associated pulmonary aspergillosis, hematological malignancy, mechanical ventilation, intensive-care-unit admission and a GM index above 0.5 were each linked with worse clinical results. After the researchers adjusted for multiple variables, two factors remained independently associated with poor outcome: hematological malignancy and ICU admission. Patients with a blood cancer had an odds ratio of 3.340 for poor outcome, with a 95 percent confidence interval from 1.286 to 8.674. ICU admission had an even stronger association, with an odds ratio of 5.861 and a 95 percent confidence interval from 2.715 to 12.652. These figures describe associations rather than guaranteed outcomes, but they highlight how strongly underlying immune dysfunction and critical illness shape the course of pulmonary aspergillosis.

The biological relationship between severe respiratory viral illness and Aspergillus infection is complex. Viral damage can disrupt the airway lining, alter mucus clearance and impair the local immune cells that normally contain inhaled spores. Severe illness may also bring exposure to corticosteroids, broad-spectrum antibiotics, mechanical ventilation and prolonged ICU care, each of which can change the microbial and immune environment of the lungs. Similar concerns emerged during severe influenza, when influenza-associated pulmonary aspergillosis became a recognized complication. COVID-19-associated pulmonary aspergillosis has likewise been reported in critically ill patients, although definitions and diagnostic criteria have varied between studies. The new retrospective analysis adds a longer time frame, showing not only individual cases linked to viral illness but also a broader rise in the hospital population diagnosed with pulmonary aspergillosis during the pandemic era.

The researchers emphasize that pulmonary aspergillosis includes invasive, chronic and allergic forms, and that future studies must separate these categories when evaluating prognosis. Combining all forms into one analysis may obscure major differences in risk, treatment and survival. A patient with chronic disease in a pre-existing cavity has a very different clinical trajectory from a neutropenic patient with rapidly invasive infection, while allergic bronchopulmonary aspergillosis requires an immune-directed approach rather than treatment designed solely to eradicate tissue invasion. The study’s single-center retrospective design, incomplete detail about disease subtypes and reliance on hospital records limit the conclusions that can be drawn. Even so, the findings deliver a warning with broad relevance: as hospitals continue managing the consequences of pandemic-era respiratory disease, fungal pneumonia may represent a growing and underrecognized burden. Earlier testing, careful interpretation of fungal biomarkers and rapid treatment for high-risk patients could be crucial, particularly when hematological malignancy or critical illness is present.